World ADC San Diego 2026: Inside Oncology's Flagship Antibody-Drug Conjugate Summit

What This Article Covers

This week, San Diego hosts the 17th annual World ADC San Diego conference (October 12–15, 2026), the long-running industry gathering organized by Hanson Wade that tracks the fast-moving field of antibody-drug conjugates (ADCs) and the newer conjugate formats built on the same logic — attaching a cell-killing or immune-activating payload to an antibody that homes in on cancer cells. This article previews what the meeting covers, who shows up, and why the direction of this research matters for patients weighing targeted cancer treatments.

What the Event Is

World ADC San Diego is a four-day meeting held at the Town and Country Resort in San Diego, California, drawing scientists, clinicians, and biopharma executives working on ADCs — drugs that pair a monoclonal antibody with a cytotoxic payload, designed to deliver chemotherapy-like potency directly to tumor cells while sparing healthy tissue. Organizers describe it as the field's largest and most comprehensive dedicated ADC forum; that framing is Hanson Wade's own characterization rather than an independently audited ranking, but the conference's multi-decade run and broad content footprint are well documented. The 2026 edition is structured around seven content tracks: Discovery Chemistry, Discovery Biology, Preclinical, Translational Medicine, Clinical Lessons, Process & Analytical Development, and Manufacturing & Supply — spanning the full path from early molecule design to commercial-scale production.

Who Attends and What They Focus On

Attendees range from bench chemists optimizing linker and payload chemistry to clinical teams reporting trial data and manufacturing specialists solving supply-chain bottlenecks. The agenda reflects how crowded and technically diverse the ADC space has become: sessions this year cover not just classic ADCs but adjacent engineered formats, including degrader-antibody conjugates (DACs), immune-stimulating antibody conjugates (ISACs), antibody-oligonucleotide conjugates (AOCs), bispecific ADCs, dual-payload ADCs, and conditionally active designs meant to reduce off-target toxicity.

What to Expect This Year

A stated goal of the 2026 program is pushing ADCs into earlier lines of cancer treatment rather than reserving them for patients who have exhausted other options. Clinical content includes discussion of I-SPY2 trial data in triple-negative and HER2-positive breast cancer, along with sessions on combining ADCs with antibody-based immunotherapies for solid tumors — an area where ADC payload delivery and immune-system engagement increasingly overlap. Preclinical talks are expected to dig into newer payload classes, including pan-PI3K/mTOR inhibitors, protein-alkylating agents, antifolates, and translation inhibitors, reflecting a push beyond the handful of payload chemistries that dominated the ADC class's first wave.

Why It Matters for the Field

ADCs have gone from a niche modality to one of oncology's most active development categories, and conferences like this one are where incremental technical fixes — a more stable linker, a cleaner payload release mechanism — get surfaced well before they show up in headline trial results. For patients and caregivers tracking next-generation cancer therapeutics, the clinical and translational sessions here are a reasonable leading indicator of which approaches are gaining real momentum versus stalling in early development.

Bottom Line

World ADC San Diego 2026 is a legitimate, well-established industry meeting — not a patient-facing event — but its agenda offers a useful, verifiable window into where antibody-drug conjugate research is actually headed, from payload chemistry to combination strategies with immunotherapy. As with any conference preview, the specific data and claims presented during the sessions themselves will need their own scrutiny once published.